GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference
05 September 2023 - 1:00PM
Business Wire
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout
Semerjian, Chief Executive Officer, will present at the H.C.
Wainwright 25th Annual Global Investment Conference in New York, NY
on Wednesday, September 13, 2023 at 11:30 a.m. ET.
A live webcast of the presentation will be available on the
GlycoMimetics website at
https://ir.glycomimetics.com/investor-relations. An archived
recording will be available for 30 days following the event.
About GlycoMimetics, Inc.
GlycoMimetics is a late clinical-stage biotechnology company
discovering and developing glycobiology-based therapies for
cancers, including AML, and for inflammatory diseases. The
company’s science is based on an understanding of the role that
carbohydrates play in cell recognition. Its specialized chemistry
platform is being deployed to discover small molecule drugs--known
as glycomimetics--that alter carbohydrate-mediated recognition in
diverse disease states, including cancers and inflammation. As a
leader in this science, GlycoMimetics leverages this unique
approach to advance its pipeline of wholly-owned drug candidates,
with the goal of developing transformative therapies for diseases
with high unmet medical need. GlycoMimetics is headquartered in
Rockville, MD in the BioHealth Capital Region. Learn more at
www.glycomimetics.com.
Forward-Looking Statements
This press release contains forward-looking statements. These
forward-looking statements may include, but are not limited to,
statements regarding the conduct of and data from clinical trials,
planned or potential clinical development, regulatory interactions
and submissions, the commercialization and potential benefits and
impact of the Company’s drug candidates, and the Company’s expected
cash runway. Actual results may differ materially from those
described in these forward-looking statements. For a further
description of the risks associated with these statements, as well
as other risks facing GlycoMimetics, please see the risk factors
described in the Company’s Annual Report on Form 10-K filed with
the U.S. Securities and Exchange Commission (SEC) on March 3, 2022,
its Quarterly Report on Form 10-Q filed with the SEC on November 9,
2022, and other filings GlycoMimetics makes with the SEC from time
to time. Forward-looking statements speak only as of the date of
this release, and GlycoMimetics undertakes no obligation to update
or revise these statements, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230905756277/en/
Investors: Argot Partners Leo Vartorella 212-600-1902
Glycomimetics@argotpartners.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
Von Mai 2023 bis Mai 2024